• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad June 12 Cadila Healthcare Ltd (Zydus Cadila) has received three product approvals from the US Food and Drug Administration, the company said in a release here today.

The group has received approvals to market Benzonatate capsules in 100 and 200 mg, Naproxen tablets and a tentative approval for Amlodipine Besylate tablets in 2.5, 5 and 10 mg.

The group will market all three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Zydus Cadila gets USFDA nod for new products

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line